Abstract. The pharmacodynamics of plasma testosterone (T) and androstenedione (A) levels were studied in ten hypogonadal boys after oral administration of testosterone undecanoate (TU).
Plasma T and A levels were measured by specific radioimmunoassays. Six hours after a single dose of 120 mg TU, there was a significant increase (P < 0.005) in plasma T and A with a median T peak level of 940 ng/100 ml. Furthermore, twelve agonadal boys treated with a mean dose of 60 mg TU/day were examined over a period of 18\p=n-\24months. During this therapy, plasma T and A levels were significantly higher than before (P < 0.005), whereas plasma levels of LH and FSH did not decrease significantly. With the exception of one anorchic boy, all patients showed signs of sexual maturation, such as growth of pubic and axillary hair, and steady development of bone age during oral TU treatment.
The replacement therapy of testosterone (T) in patients suffering from deficient endocrine func¬ tion of the testes is characterized by the following disadvantages : The oral administration of genuine T is rather ineffective due to the rapid metabolism of the hormone both in the liver and in the intestinal wall (Foss & Camb 1939; Harri et al. 1970 ). Recenüy, however, Johnsen et al. (1974) have shown that 200 mg of oral T can produce normal male serum T levels for 5-7 h in eunuchs and therefore might be a useful form of androgen therapy (Johnsen 1978) .
Synthetic methyl-testosterone is orally active, but may lead to liver dysfunction, such as jaundice or cirrhosis (Werner et al. 1950; Glover & Wilkinson 1968) .
The injection of long-acting testosterone esters is not only inconvenient but also painful, particularly for children, and invariably results in unphysiologically high and fluctuating levels of T (Aakvaag & Vogt 1969) .
Recent studies both in rats ) and in adult males (Nieschlag et al. 1975; Franchimont et al. 1978) Greulich & Pyle (1959 (Fig. 1) . Between 2 and 9 h median T concentrations reached the normal range of healthy adult males (Knorr et al. 1974) . No difference in plasma T levels could be seen between the previously TU treated and the untreated patients. Plasma A levels also increased significantly (P < 0.005) and concomitantly to T, yet, the peak of median A levels occurred 3 h earlier than the T peak (Fig. 1) .
Under different doses of TU administered, plasma T levels increased markedly (Fig. 2, top) . Although there was wide individual variation, all boys reached at least the lower limit of the normal adult male T range. After 24 h, control levels were observed in all patients. Plasma A levels increased in a similar pattern (Fig. 2, bottom) . As shown in Fig. 4 , the plasma levels of T and A were significantly higher during TU replacement than before therapy (P < 0.005). However, during treatment there was a wide individual fluctuation of T levels, ranging from 15 up to 860 ng/100 ml.
The concentrations of testosterone after 6, 12, 18 and 24 months of therapy did not differ signifi¬ cantly from each other.
AH patients not previously treated with androgens (pubertal stage 1) exhibited a steady develop¬ ment of pubic and axillary hair during TU treat¬ ment, with the exception of one boy (Fig. 5) . The other boys who previously had been given other preparations of androgens showed further sexual development during TU administration. "is" 
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Months of TU-Treatment Development of pubic and axillary hair in agonadal boys (n = 6, not treated with androgens previously) during treatment with an average daily dose of 60 mg TU. Bone maturation advanced gradually in all pa¬ tients during the observation period (Fig. 6) (Fig. 1) .
The parallel rise of plasma testosterone and androstenedione levels found by Nieschlag et al. (1975) and confirmed in the present study is obvi¬ ously due to the rapid conversion of testosterone to androstenedione (Horton & Tait 1966; Baird et al. 1969) . Mies & Krempl (1977) and Franchimont et al. (1978) reported marked and progressive increases of plasma T in adult hypogonadal males after 3, 6 and 9 weeks of TU administration. The doses used ranged between 120 and 240 mg TU/day. According to our data, plasma T levels in agonadal boys rose significantly during long-term TU therapy (Fig. 4) . But the present results did not indicate a further T increase after 6, 12, 18 and 24 months of therapy with a mean dose of 60 mg TU/day.
In our patients, a great variation in individual plasma T levels was seen during continuous TU replacement therapy (Fig. 4) . These relatively large fluctuations are partly a consequence of the lack of a precise daily time schedule between drug admini¬ stration and blood sampling. Furthermore, there were considerable differences in the individual plasma T increases after administration of the same TU dose ( Fig. 1 and 2) . Therefore, the measurement of a single plasma T level a day is of only limited value for the biochemical assessment of androgen replacement therapy.
A mean dose of 60 mg TU/day administered over a period of 18-24 months did not significantly decrease the hypergonadotrophic LH and FSH levels found in agonadal boys (Fig. 3) . This finding is in contrast to the study of Franchimont et al. (1978) 
